JPRN-jRCT2031180172进行中（未招募）1 期
A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma - FRONTiER
Kato Ken0 个研究点目标入组 36 人开始时间: 2019年3月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1) Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous cell carcinoma, adenosquamous carcinoma or basal cell carcinoma
- •2) All esophageal cancer lesions are localized in the thoracic esophagus
- •3) Patients are classified as clinical stage T1N1-3M0 or T2-3N0-3M0 in the UICC-TNM classification 8th edition
- •4) The age is over 18 years old and under 75 on the enrollment date
- •5) PS 0-1
- •6) With or without measurable lesions
- •7) Patients who have no medical history of treatment for esophageal cancer
- •8) Patients who have no medical history of chemotherapy, radiotherapy and endocrine therapy including treatment for other types of cancer
- •9) The results of laboratory tests within 14 days before enrollment meet the inclusion criteria
- •10) Esophageal cancer radical surgery (R0) by open-chest surgery (or thoracoscopic surgery) and laparotomy (or laparoscopic surgery) is judged possible
- •11) Patients who have no complication or history of thyroid dysfunction
- •12) Patients who have no complication or history of autoimmune disease
- •13) Patients who have no complication or history of active tuberculosis
- •14) Patients who don't have treatment with systemic corticostroids (dose of 10mg/day over in prednisolone equivalent) or imunosuppressants within 14 days before enrollment
- •15) Patinets who have no complication or hisoty of pneumonitis or pulmonary fibrosis which had been diagnosed by imaging tests or phisical examination
- •16) Females who have agreed with contraception and not to donate oocytes from their consent participation of the study, until 5 months after the last dose of nivolumab, 14 months after the last dose of cisplatin, or 9 months after the last dose of oxaliplatin, whichever is later. Males who have agreed with contraception and not to donate sperms from start of cisplatin or oxaliplatin administration, until 11 months after the last dose of cisplatin, or 6 months after the last dose of oxaliplatin, whichever is later
- •17) Obtained the written informed consent from patients
排除标准
- •1) Patients who have active multiple cancers
- •2) Patients who have infectious disease which is active and need the systemic treatment
- •3) Positive with HBs antigen, or HCV-RNA or anti HIV antibody, or anti HTLV-1 antibody tests
- •4) Negative with HBs antigen test and positive with anti HBs antibody or anti HBc antibody tests, and positive with HBV-DNA quantitative test
- •5) Pregnant, suspected pregnant or lactating
- •6) Patients who have Psycosis or psychiatric symptoms are judged inappropriate for paticipation of the trial
- •7) Patients who need the treatment with continued use of flucytosine, phenytoin or warfalin pottasium
- •8) Patients who have a medical history of allergy to iodine
- •9) Patients who have hypersensitivity to docetaxel, cisplatin, oxaliplatin, and drug containing polysorbate 80
- •10) Patients who have a complication or a history of highly sensitive reactions to antibody formulations
- •11) Even if insulin or oral hypoglycemic agent is continued to use, the result of HbA1c test is 6.5% or more in JDS or 6.9% or more in NGSP
- •12) Patients who have advanced pulmonary emphysema which is observed by pulmonary function test or CT test
- •13) Patients who have uncontrollable hypertension
- •14) Patients who have unstable angina or a medical history of myocardial infarction within 6 months before for enrollment
- •15) Patients who have diverticulitis or symptomatic peptic ulcer disease
- •16) Patients who have history of transplantation therapy such as hematopoietic stem cell transplantation
- •17) Patients who have medical history of treatment with anti PD-1 antibody, anti PD-L1 antibody, anti PD-L2 antibody, anti CD137 antibody, anti CTLA-4 antibody or any other antibody for inhibition or modulation of T cell costimulatory pathway or cancer vaccine
- •18) The patient received or is scheduled to receive live or attenuated vaccine within 28 days prior to the first dose of nivolumab
研究者
相似试验
尚未招募
2 期
Evaluation of low dose immunotherapy for lung cancerCTRI/2023/02/050126Indian Council of Medical Research
已完成
1 期
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaNCT03914443National Cancer Center, Japan37
招募中
不适用
The trial of neoadjuvant nivolumab, docetaxel, cisplatin therapy followed by surgery and radiation therapy for resectable high grade salivary gland carcinomaKCT0007702Samsung Medical Center50
进行中（未招募）
1 期
Treatment of advanced lung cancerPatients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059514Term: Small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003334-25-DEniversity of Cologne90
进行中（未招募）
1 期
ivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade gliomaewly diagnosed High-Grade Gliomas (HGG)MedDRA version: 20.0 Level: PT Classification code 10065443 Term: Malignant glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10018338 Term: Glioma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002688-24-FRGustave Roussy40